<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02270801</url>
  </required_header>
  <id_info>
    <org_study_id>rhTPO-ITP-Pregnancy</org_study_id>
    <nct_id>NCT02270801</nct_id>
  </id_info>
  <brief_title>Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy</brief_title>
  <official_title>Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is undertaking by Qilu Hospital of Shandong University, aims at&#xD;
      evaluating efficacy and safety of rhTPO in management of ITP in pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are undertaking a single-center, non-randomized, non-controlled trial of 30&#xD;
      ITP patients in pregnancy from Qilu Hospital of Shandong University. ITP patients in&#xD;
      pregnancy who failed to respond to prednisone, IVIG and developed refractoriness to platelet&#xD;
      transfusion will be given rhTPO intravenously at a dose of 300U/kg every day. Dose will be&#xD;
      tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will&#xD;
      be continued after delivery and the dose will be further reduced to 300U/kg per week.&#xD;
      Platelet count, bleeding and other symptoms will be evaluated before and after treatment.&#xD;
      Adverse events will be recorded throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Response</measure>
    <time_frame>one month after delivery</time_frame>
    <description>Response rate (CR+R) at the 14th day, the 10th week from the initial injection of rhTPO, ante partum and one month after delivery. CR is defined as platelet count ≥ 100×109/L, and R is defined as platelet count of &gt;30×109/L with at least a doubling of the baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>six months after delivery</time_frame>
    <description>Adverse events in patients and infants.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>rhTPO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhTPO</intervention_name>
    <description>rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.</description>
    <arm_group_label>rhTPO</arm_group_label>
    <other_name>TPIAO</other_name>
    <other_name>S20050048/49 (SFDA, China)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is between 18-50 years old.&#xD;
&#xD;
          2. After 12 weeks gestation.&#xD;
&#xD;
          3. Diagnosed with ITP meeting the diagnostic criteria for immune thrombocytopenia.&#xD;
&#xD;
          4. Patients who have no response or relapsed after Corticosteroid or IVIG.&#xD;
&#xD;
          5. Patients developed refractoriness to platelet transfusion.&#xD;
&#xD;
          6. To show a platelet count &lt; 30×10^9/L, and with bleeding manifestations.&#xD;
&#xD;
          7. Willing and able to sign written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts&#xD;
             within 3 months before the screening visit.&#xD;
&#xD;
          2. Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine,&#xD;
             vincristine, vinblastine, etc) within 3 months before the screening visit.&#xD;
&#xD;
          3. Current HIV infection or hepatitis B virus or hepatitis C virus infections.&#xD;
&#xD;
          4. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP.&#xD;
             Unstable or uncontrolled disease or condition related to or impacting cardiac function&#xD;
             (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac&#xD;
             arrhythmia)&#xD;
&#xD;
          5. Have a known diagnosis of other autoimmune diseases, established in the medical&#xD;
             history and laboratory findings with positive results for the determination of&#xD;
             antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct&#xD;
             Coombs test.&#xD;
&#xD;
          6. Patients who are deemed unsuitable for the study by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Hou, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Hou, MD PhD</last_name>
    <phone>86-531-82169114</phone>
    <phone_ext>9879</phone_ext>
    <email>houming@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shandong University Qilu hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Hou, MD PhD</last_name>
      <phone>+86-531-82169114</phone>
      <phone_ext>9879</phone_ext>
      <email>houming@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Ming Hou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>October 17, 2014</study_first_submitted>
  <study_first_submitted_qc>October 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Ming Hou</investigator_full_name>
    <investigator_title>Professor and Director</investigator_title>
  </responsible_party>
  <keyword>recombinant human thrombopoietin</keyword>
  <keyword>immune thrombocytopenia</keyword>
  <keyword>pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

